Company Growth (employees)
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, US
Regeneron Pharmaceuticals Office Locations
Regeneron Pharmaceuticals has offices in Tarrytown, Rensselaer, Bernards, Limerick and in 1 other location
Tarrytown, US (HQ)
777 Old Saw Mill River Rd
Dublin, IE
Harcourt Centre Harcourt St
Bernards, US
110 Allen Rd
Rensselaer, US
81 Columbia Turnpike
Regeneron Pharmaceuticals Data and Metrics
Regeneron Pharmaceuticals Financial Metrics
Regeneron Pharmaceuticals's revenue was reported to be $1.3 b in Q1, 2017
USD
Revenue (Q1, 2017) | 1.3 b |
Gross profit (Q1, 2017) | 1.3 b |
Gross profit margin (Q1, 2017), % | 95% |
Net income (Q1, 2017) | 248.9 m |
EBIT (Q1, 2017) | 430.5 m |
Market capitalization (18-Aug-2017) | 54.3 b |
Cash (31-Mar-2017) | 811.8 m |
Regeneron Pharmaceuticals's current market capitalization is $54.3 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 2.1 b | 2.8 b | 4.1 b | 4.9 b |
Revenue growth, % | 34% | 46% | 18% | |
Cost of goods sold | 118 m | 129 m | 241.7 m | 194.6 m |
Gross profit | 2 b | 2.7 b | 3.9 b | 4.7 b |
Gross profit Margin, % | 94% | 95% | 94% | 96% |
R&D expense | 2.1 b | |||
Operating expense total | 2.1 b | |||
EBIT | 760 m | 838.4 m | 1.3 b | 1.3 b |
EBIT margin, % | 36% | 30% | 31% | 27% |
Interest expense | 46.4 m | 37.4 m | 14.2 m | 7.2 m |
Pre tax profit | 713.4 m | 775.7 m | 1.2 b | 1.3 b |
Income tax expense | (289 m) | (427.7 m) | (589 m) | (434.3 m) |
Net Income | 424.4 m | 348.1 m | 636.1 m | 895.5 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 665.7 m | 725.8 m | 869.6 m | 998.6 m | 1.1 b | 1.2 b | 1.2 b | 1.2 b | 1.3 b |
Cost of goods sold | 29.9 m | 33.7 m | 42.6 m | 60.9 m | 67.2 m | 78.9 m | 41.2 m | 29.9 m | 61.3 m |
Gross profit | 635.8 m | 692.1 m | 827 m | 937.8 m | 1.1 b | 1.1 b | 1.2 b | 1.2 b | 1.3 b |
Gross profit Margin, % | 96% | 95% | 95% | 94% | 94% | 93% | 97% | 98% | 95% |
R&D expense | 294.5 m | 337.7 m | 343.1 m | 390.3 m | 425.9 m | 470.1 m | 559.9 m | 543 m | 507.4 m |
EBIT | 222.4 m | 182.7 m | 283.6 m | 344.9 m | 392.4 m | 329.3 m | 291.6 m | 362.8 m | 430.5 m |
EBIT margin, % | 33% | 25% | 33% | 35% | 35% | 27% | 24% | 30% | 33% |
Pre tax profit | 203.1 m | 176.1 m | 276.5 m | 328 m | 393.3 m | 330.2 m | 292.3 m | 365.9 m | 432.3 m |
Net Income | 158.2 m | 237.9 m | 76 m | 270.7 m | 481.1 m | 165.7 m | 377.6 m | 642.4 m | 248.9 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 535.6 m | 648.7 m | 809.1 m | 535.2 m |
Inventories | 70.4 m | 128.9 m | 238.6 m | 399.4 m |
Current Assets | 1.8 b | 2.2 b | 2.9 b | 3.2 b |
PP&E | 2.1 b | |||
Total Assets | 3 b | 3.9 b | 5.6 b | 7 b |
Accounts Payable | 250.9 m | 484.2 m | 644.1 m | 879.1 m |
Current Liabilities | 298.8 m | 654.7 m | 811.2 m | 1.2 b |
Total Liabilities | 2.5 b | |||
Common Stock | 2 k | 2 k | 2 k | 2 k |
Additional Paid-in Capital | 2 b | 2.4 b | 3.1 b | 3 b |
Retained Earnings | (92.7 m) | 255.4 m | 852.7 m | 1.7 b |
Total Equity | 2 b | 2.5 b | 3.7 b | 4.4 b |
Financial Leverage | 1.5 x | 1.5 x | 1.5 x | 1.6 x |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 600.1 m | 646.6 m | 507.9 m | 390.6 m | 654.6 m | 604.2 m | 646.5 m | 920.4 m | 811.8 m |
Inventories | 109.9 m | 120.3 m | 133.9 m | 171.3 m | 190.7 m | 303.3 m | 316.1 m | 345.6 m | 466.6 m |
Current Assets | 1.9 b | 2.2 b | 2.3 b | 2.3 b | 2.7 b | 3.1 b | 3.2 b | 3.5 b | 3.7 b |
PP&E | 1.7 b | 1.8 b | 1.9 b | 2.3 b | |||||
Total Assets | 3.5 b | 3.7 b | 4.2 b | 4.5 b | 5.2 b | 5.9 b | 6.2 b | 6.8 b | 7.8 b |
Accounts Payable | 283.4 m | 338 m | 462.8 m | 529.5 m | 577.4 m | 733.3 m | 759.6 m | 714.9 m | 1.1 b |
Current Liabilities | 351.6 m | 410.2 m | 536.1 m | 601.5 m | 735 m | 919.7 m | 951.6 m | 961.2 m | 1.3 b |
Common Stock | 2 k | 2 k | 2 k | 2 k | 2 k | 2 k | 2 k | 2 k | 2 k |
Additional Paid-in Capital | 2.3 b | 2.4 b | 2.8 b | 3.1 b | 2.9 b | 3 b | 3.2 b | 3.3 b | 3.2 b |
Retained Earnings | 65.5 m | 145.2 m | 292.7 m | 487.3 m | 697.7 m | 1 b | 1.2 b | 1.5 b | 2 b |
Total Equity | 2.4 b | 2.6 b | 3 b | 3.3 b | 3.3 b | 3.8 b | 4.1 b | 4.5 b | 4.9 b |
Financial Leverage | 1.5 x | 1.5 x | 1.4 x | 1.4 x | 1.6 x | 1.6 x | 1.5 x | 1.5 x | 1.6 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 424.4 m | 348.1 m | 636.1 m | 895.5 m |
Depreciation and Amortization | 41.2 m | 52.7 m | 74.9 m | 104.7 m |
Inventories | (48 m) | (61 m) | (110 m) | (149.8 m) |
Cash From Operating Activities | 583.6 m | 743.2 m | 1.3 b | 1.5 b |
Capital Expenditures | (156.3 m) | (333 m) | (677.9 m) | (511.9 m) |
Cash From Investing Activities | (355.5 m) | |||
Cash From Financing Activities | (209.3 m) | (262.8 m) | (700.4 m) | |
Interest Paid | 23.8 m | 20.6 m | 10.6 m | 5.5 m |
Income Taxes Paid | 59.8 m | 276.1 m | 481.4 m | |
Free Cash Flow | 740 m | 1.1 b | 2 b | 961.5 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 158.2 m | 237.9 m | 76 m | 270.7 m | 481.1 m | 165.7 m | 377.6 m | 642.4 m | 248.9 m |
Depreciation and Amortization | 24.5 m | 38.6 m | 16 m | 31.3 m | 52 m | 23 m | 48 m | 75.8 m | 38.1 m |
Inventories | (37.3 m) | (50.9 m) | (5.9 m) | (49.9 m) | (81.5 m) | (62.3 m) | (72.9 m) | (99.7 m) | (69.7 m) |
Cash From Operating Activities | 381.3 m | 544.9 m | (87.5 m) | 156.1 m | 1 b | 29.3 m | 444.5 m | 1.1 b | 355.9 m |
Capital Expenditures | (135.7 m) | (215.5 m) | (114.2 m) | (354.1 m) | (500.2 m) | (104.1 m) | (242.9 m) | (361.5 m) | (50.5 m) |
Cash From Investing Activities | (354.4 m) | (477.4 m) | (129.5 m) | (501.1 m) | (784.3 m) | (43.7 m) | (369.7 m) | (775.5 m) | (140.1 m) |
Cash From Financing Activities | 37.6 m | 43.5 m | 76.2 m | 86.9 m | (258.8 m) | (190.5 m) | (237.4 m) | 60.8 m | |
Free Cash Flow | 245.6 m | 329.4 m | (201.7 m) | (198 m) | 548.8 m | (74.8 m) | 201.6 m | 734 m | 305.4 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 244.3 k |
Financial Leverage | 1.6 x |
Regeneron Pharmaceuticals Market Value History
Regeneron Pharmaceuticals Median Salaries
Source: 186 public H-1B filings from Regeneron Pharmaceuticals
Market Position of Regeneron Pharmaceuticals
Traffic Overview of Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Online and Social Media Presence
Regeneron Pharmaceuticals News and Updates
March 22, 2017
Domino’s stock has outperformed Google, Facebook, Apple, and Amazon this decade
It’s 2010. You’re an eager investor presented a choice between two stocks: Google or Domino’s pizza company. Where do you put your money? You should…
January 06, 2017
US Stocks Dip as December Hiring Report Fails to Inspire
U.S. stocks are dipping Friday morning after a solid but unspectacular hiring report for December. While employers kept hiring and hourly pay jumped, it wasn't enough to allay investors' concerns about slow economic growth. Bond yields are climbing as investors think the report shows interest rates …
January 06, 2017
Regeneron, Sanofi to Appeal US Judge's Ban on Cholesterol Drug Sales
Regeneron Pharmaceuticals Inc and Sanofi SA said on Thursday they would appeal the U.S. District Court ruling which banned the two companies from selling their cholesterol drug, Praluent, on grounds of patent infringement.
December 09, 2016
Wary Drug Makers Move to Fend Off Further Attacks Under Donald Trump
Even before the president-elect vowed “to bring down drug prices,” many companies began taking a pre-emptive approach on pricing.
December 07, 2016
Donald Trump Sent Biotech Stocks Plummeting with These 16 Words
His drug price comments rattled investors.
December 02, 2016
Mylan’s CEO Is Right—Pharma’s Price Hikes Could Ultimately Lead to Some Good
From within or without, change may actually be coming.